Jan 03, 2018 theres a new medicine atop pharmas global pricing charts, and its spark therapeutics brandnew gene therapy. Celebrating foundation fighting blindness work in the community and the illumination. Spark therapeutics luxturna advisory committee vote sets. The company is also advancing toward the clinic with gene therapy programs to address neurodegenerative diseases and additional hematologic disorders and other. Once says it will not announce the price of its newly approved injected gene therapy for retinal dystrophy until january but results of clinical trials would justify a. The treatment, luxturna, is made by philadelphiabased spark therapeutics.
Spark therapeutics in philadelphia developed the therapy in collaboration with researchers at the university of pennsylvania and childrens hospital of philadelphia. May 27, 2016 spark therapeutics is one of several companies working on gene therapies. Blindness is a cruel fate, but what if it could be treated. A new drug, luxturna, literally allows blind people to see. In the companys key study, 21 patients with retinal dystrophy caused by biallelic mutations in the rpe65 gene. An emerging gene therapy for the treatment of inherited blindness. Spark therapeutics acquires retinitis pigmentosa gene therapy. Community story authors spark therapeuticss asharedvision. A gene therapy that could cure blindness is on the brink of.
Spark therapeutics revolutionary gene therapy for blindness. Dec 20, 2017 the approval for spark therapeutics offers a lifechanging intervention for a small group of patients with a visiondestroying genetic mutation and hope for many more people with other inherited. View the latest once financial statements, income statements and financial ratios. Perhaps this year, spark therapeutics could be the first ever in the u. Katherine high is leaving the philadelphia gene therapy company after seven years leading its groundbreaking product development activities. While luxturna is a novel drug, its price tag is controversial. Oct 11, 2017 october 10, 2017 by mark terry, breaking news staff philadelphia thursday, oct.
Spark therapeutics is now member of the roche group. Shares of spark jumped 70 percent in premarket trading following the report. Spark therapeutics gene therapy for blindness moves forward with fda the groundbreaking treatment is another step ahead for a city already at the forefront of. Oct 22, 20 spark will assume control over two gene therapy clinical trials. Its products include luxturna voretigene neparvovec for the treatment of patients with confirmed biallelic rpe65 mutationassociated retinal dystrophy and viable retinal cells. Spark therapeutics sets price of blindnesstreating gene therapy.
At spark therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative. The company offering a breakthrough blindness treatment. A natural history study has shown that people with this ird eventually progress to complete blindness. Katherine high, md, president, chief scientific officer, and a founder of spark therapeutics, agrees.
Prior to joining the foundation fighting blindness in 2011, dr. On december 19, 2017, the us fda approved a new gene therapy to treat children and adults with a genetic condition that often results in blindness. Blindness gene therapy price tag stirs controversy formulary watch. Oct 12, 2017 at spark therapeutics, a fully integrated company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness. Spark therapeutics gene therapy for a rare blindness gets.
Spark therapeutics is moving forward with its treatment for a type of inherited retinal dystrophy. We are committed to delivering patient services that are as innovative and insightful as our cuttingedge gene therapy. It does not give 2020 vision or work for everyone, but a companyfunded study found it improved vision for nearly all. Fda approves novel gene therapy to treat patients with a rare form of. Spark therapeutics is expected to seek approval next year for a gene therapy to cure a disease that leads to blindness. View todays stock price, news and analysis for spark therapeutics inc.
When she was 12, doctors determined that mistys blindness had a genetic. So what sparks stock surged when spk8011 produced some encouraging data earlier this year. The lead therapy is for rpe65related blindness, with. Spark will assume control over two gene therapy clinical trials. Luxturna, a novel therapy approved by the fda last year, treats a rare form of inherited blindness known as retinitis pigmentosa. Spark therapeutics announces positive topline results from. Fda approves sparks gene therapy for rare blindness. Spark therapeutics gene therapy offering fresh hope to. Fda approves gene therapy for inherited blindness developed. Spark therapeutics stock has fallen about 40% as of 11.
View realtime stock prices and stock quotes for a full financial overview. In a novel arrangement, spark will offer discounts based on whether or. Fda approves novel gene therapy to treat patients with a rare form of inherited vision loss. Spark therapeutics luxturna voretigene neparvovecrzyl is a onetime gene therapy product that treats biallelic rpe65 mutationassociated retinal dystrophy, an inherited retinal disease that frequently progresses to. Spark therapeutics luxturna to cure rare blindness for. Theres a new medicine atop pharmas global pricing charts, and its spark therapeutics brandnew gene therapy. I spoke with her earlier this week about the recent progress. The approval for spark therapeutics offers a lifechanging intervention for a small group of patients with a visiondestroying genetic mutation and hope for many more people with other inherited. Spark therapeutics latestage gene therapy for inherited. Once stock spark therapeutics stock price today markets. October 12, 2017 fda advisory committee meeting page 1 of 149 fda advisory committee briefing document spark therapeutics, inc. In november 2017, spark therapeutics welcomed the foundation fighting blindness ffb to host an exclusive screening of the illumination, a powerful documentary chronicling the origin of the ffb, its founders and its quest to help create a new field in vision science, one that is seeking to deliver on the.
Spark therapeutics, a philadelphia biotechnology company created in 20 by chop in an effort to accelerate the timeline for bringing new gene therapies to market, led the latestage clinical development of luxturna and built in west philadelphia the first licensed manufacturing facility in the u. A new treatment for blindness comes from gene therapy. At spark therapeutics, we challenge the inevitability of genetic disease. However, spark therapeutics is charging as much for luxturna as they think. How a small biotechs antiblindness quest may also bring. She is a cofounder, president and chief scientific officer of spark therapeutics. Spark therapeutics gene therapy hits goals in blindness study. Spark therapeutics gained the first food and drug administration approval for a gene therapy on tuesday a onetime treatment for an eye disease that generally progresses to. Spark therapeutics, spark therapeutics generation patient services sm, and you. Jul 20, 2017 a natural history study has shown that people with this ird eventually progress to complete blindness. All earnings call transcripts on spark therapeutics, inc.
Dec 24, 2019 blindness is a cruel fate, but what if it could be treated. In 20, the team founded spark therapeutics, a biotech firm, to develop and fund. The companys treatment for a genetic retinal disease shows promise in treating blindness. Spark therapeutics gene therapy for blindness moves forward. Spark therapeutics sets price of blindnesstreating. Barrons also provides information on historical stock ratings, target prices, company earnings, market valuation. Mansfield was the chief scientist and vice president for research and development for correlogic systems, inc. Spark therapeutics receives rare pediatric disease. Download the investor presentation earnings call slides. The doctor says at the end of the book that he doesnt believe that they never went blind. October 10, 2017 by mark terry, breaking news staff philadelphia thursday, oct.
It does not give 2020 vision or work for everyone, but a companyfunded study found it. Kathy high spark therapeutics so i believe that luxturna to treat rpe65 blindness will still be the first actual gene therapy approval. Inherited retinal dystrophies irds are a major cause of earlyonset blindness. In a historic step, the food and drug administration on tuesday approved spark therapeutics inc. So what spark s stock surged when spk8011 produced some encouraging data earlier this year. Voretigene neparvovec, developed by spark therapeutics, inc. Her work primarily focused on the use of gene therapy for hemophilia. Senior vice president, research, foundation fighting blindness.
Spark therapeutics spark joins a new wave of gene therapy players out to transform medicine ceo. Nov, 2015 spark therapeutics is expected to seek approval next year for a gene therapy to cure a disease that leads to blindness. Fda approves spark blindness drug in gene therapy first. Sparks price for luxturna blindness gene therapy too high. Spark therapeutics hopes to cure a rare blindness for. Shares of gene therapy specialist spark therapeutics catapulted 120. At spark therapeutics, a fully integrated company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness. Spark therapeutics gene therapy for blindness moves forward with fda the groundbreaking treatment is another step ahead for a city already at the forefront of gene therapy development. Spark therapeutics, a small biotechnology company in the us, says it will. The fda granted approval of luxturna to spark therapeutics inc.
Spark therapeutics gains approval for first gene therapy to. High is an american doctor who is an emeritus professor of pediatrics at the perelman school of medicine at the university of pennsylvania. Spark therapeutics stock traded lower after the announcement, likely because of uncertainty about pricing. Spark therapeutics gets fda panel ok for gene therapy to.
The potential cost and payment model of that treatment is already stirring. Pioneering gene therapy restores vision to people with rare. Spark wont announce a price for the treatment until after the first of the year. Spark therapeutics is one of several companies working on gene therapies. The proposed price for spark therapeutics incs groundbreaking onetime gene therapy for a rare form of blindness is far too high. The gene therapy treats a rare, inherited retinal disease that can lead to blindness. It does it by using a virus to insert new genes into patients eyes. Spark therapeutics gained the first food and drug administration approval for a gene therapy on tuesday a onetime treatment for an eye disease that generally progresses to complete blindness. Spark therapeutics wins prix galien usa award the galien foundation has awarded spark therapeutics with the prestigious 2019 prix galien usa award for best biotechnology product science magazine names spark 2019 top biotech and pharma employer spark therapeutics ranks fifth on a list of 20. The tale of spark therapeutics shows how investing victories, not to mention seemingly miraculous medical advances, can be forged. In the wake of the fdas preliminary approval, it could be available in 2018. This morning, luxturnas maker, spark therapeutics, is announcing the cost of this medical miracle.
Spark therapeutics once trading of stock halted as fda. A gene therapy from spark therapeutics to treat a rare eye disease should gain full fda approval, reports say. The luxturna therapy improves vision for patients with a rare form of blindness called leber congenital amaurosis that affects between 1,000 and 2,000 people in the u. High, jeffrey marrazzo, and steven altschuler in an effort to commercially develop treatments against haemophilia that high was working on at. Sparks gene therapy for rare form of blindness wins. About spark therapeutics spark therapeutics, a fully integrated company, strives to challenge.
581 1227 407 866 258 1108 1495 1447 4 394 1344 699 922 892 999 1297 433 1125 258 801 1344 636 844 646 953 1569 1265 1102 638 1577 272 594 1397 674 18 392 916 924 177 1330 1499 293 80 319 264 1201